We are pleased to inform about the success of our Ph.D. student Damian Mikulski, M.D. – the results of the ATLAS clinical trial (PMC006) in which he participated were published in the Lancet Oncology (IF 54.433) in the manuscript “Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial”.
The ATLAS non-commercial trial was designed and conducted by the Polish Myeloma Consortium under the leadership of prof. Dominik Dytfeld (Poznan University of Medical Sciences), in cooperation with prof. Andrzej Jakubowiak from the University of Chicago. Its objective was to compare, in a phase 3 study, the effectiveness of two types of maintenance therapy in patients with multiple myeloma after autologous hematopoietic stem cell transplantation: the standard treatment- lenalidomide (in the control group) and a new regimen consisting of the simultaneous administration of three drugs: carfilzomib with lenalidomide and dexamethasone (study group). The study involved 159 patients from Poland and 21 from the USA. The study’s results may be a voice for changing the current standard of multiple myeloma treatment.